BridgeBio Pharma

BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers, develops and delivers medicines for genetic diseases, including rare Mendelian conditions and genetically driven cancers. It operates through a hub-and-spoke model with subsidiary companies. Its key products and candidates include acoramidis (Attruby) for transthyretin amyloid cardiomyopathy, encaleret for ADH1, infigratinib for achondroplasia, and BBP-418 for LGMD2I/R9.